
    
      The study will assess the change in pain intensity over 20 minutes from start of
      administration of PENTHROX™ and will generate Real World Evidence in support of existing
      clinical trial data including effectiveness, safety and additional parameters of low dose
      MEOF (PENTHROX™) in Canadian EDs.
    
  